Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Toxicological safety evaluation of gadobutrol.

Wack C, Steger-Hartmann T, Mylecraine L, Hofmeister R.

Invest Radiol. 2012 Nov;47(11):611-23. doi: 10.1097/RLI.0b013e318263f128.

PMID:
23011188
2.

Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.

Steger-Hartmann T, Graham PB, Müller S, Schweinfurth H.

Invest Radiol. 2006 May;41(5):449-59.

PMID:
16625108
3.

Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).

Döhr O, Hofmeister R, Treher M, Schweinfurth H.

Invest Radiol. 2007 Dec;42(12):830-41.

PMID:
18007155
4.

Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.

Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H.

Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. Review.

PMID:
8486501
5.

Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.

Voth M, Rosenberg M, Breuer J.

Invest Radiol. 2011 Nov;46(11):663-71. doi: 10.1097/RLI.0b013e3182218dc3.

PMID:
21623211
6.

Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging.

Wible JH Jr, Troup CM, Hynes MR, Galen KP, MacDonald JR, Barco SJ, Wojdyla JK, Periasamy MP, Adams MD.

Invest Radiol. 2001 Jul;36(7):401-12.

PMID:
11496095
7.

Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.

Hahn G, Sorge I, Gruhn B, Glutig K, Hirsch W, Bhargava R, Furtner J, Born M, Schröder C, Ahlström H, Kaiser S, Moritz JD, Kunze CW, Shroff M, Stokland E, Trnkova ZJ, Schultze-Mosgau M, Reif S, Bacher-Stier C, Mentzel HJ.

Invest Radiol. 2009 Dec;44(12):776-83. doi: 10.1097/RLI.0b013e3181bfe2d2.

PMID:
19858730
8.

[General toxicity study of gadobenate dimeglumine formulation (E7155) (3)--4-week repeated dose intravenous toxicity study followed by 4-week recovery period in rats].

Aoki T, Sagami F, Tirone P, Morisetti A, Bussi S, Masters RE.

J Toxicol Sci. 1999 Nov;24 Suppl 1:19-39. Japanese.

PMID:
10637778
9.

Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium.

Morisetti A, Bussi S, Tirone P, de Haën C.

J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S207-17.

PMID:
10608416
10.

Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.

Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J.

Invest Radiol. 1994 Jul;29(7):709-15.

PMID:
7960618
11.

[Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].

Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R.

Radiologe. 1995 Aug;35(8):508-16. German.

PMID:
7568795
12.

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.

von Keutz E, Schlüter G.

Am J Cardiol. 1998 Aug 27;82(4B):11J-17J.

PMID:
9737641
13.

Summary of preclinical safety evaluation of gadoteridol injection.

Soltys RA.

Invest Radiol. 1992 Aug;27 Suppl 1:S7-11.

PMID:
1506157
14.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials..

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
15.

Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.

Katakami N, Inaba Y, Sugata S, Tsurusaki M, Itoh T, Machida T, Tanaka H, Nakayama T, Morikawa T, Breuer J, Aitoku Y.

Invest Radiol. 2011 Jul;46(7):411-8. doi: 10.1097/RLI.0b013e3182145a6c.

PMID:
21467949
16.

Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging.

Vogler H, Platzek J, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Radüchel B, Press WR.

Eur J Radiol. 1995 Nov;21(1):1-10.

PMID:
8654452
17.

Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material.

Balzer JO, Loewe C, Davis K, Goyen M, Leiner T, Meaney JF, Pöckler-Schöniger C, Schulte-Altedorneburg G, Tombach B, Vosshenrich R, Wegener R.

Eur Radiol. 2003 Sep;13(9):2067-74. Epub 2002 Dec 3.

PMID:
12928957
18.

Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.

Hammerstingl R, Adam G, Ayuso JR, Van Beers B, Belfiore G, Bellin MF, Bongartz G, Ernst O, Frericks B, Giuseppetti G, Heinz-Peer G, Laghi A, Martin J, Pering C, Reimer P, Richter GM, Roemer FW, Schäfer FK, Vilgrain V, Vogl TJ, Weishaupt D, Wall A, Zech CJ, Tombach B.

Invest Radiol. 2009 Mar;44(3):168-76. doi: 10.1097/RLI.0b013e318198a0ae.

PMID:
19169143
19.

Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.

Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI.

Invest Radiol. 2010 Dec;45(12):810-8. doi: 10.1097/RLI.0b013e3181f03d8a.

PMID:
20856127
20.

[General toxicity study of gadobenate dimeglumine formulation (E7155) (2)--Single dose intravenous toxicity study in dogs].

Sekido T, Sagami F, Tirone P, Morisetti A, Bussi S, Masters RE.

J Toxicol Sci. 1999 Nov;24 Suppl 1:7-18. Japanese.

PMID:
10637777

Supplemental Content

Support Center